Immunome vs Xenon Pharmaceuticals
Xenon Pharmaceuticals reported revenue of $8 million in fiscal 2025, about the same as Immunome's $7 million in fiscal 2025. Immunome had an operating margin of -3228.8%, against -4974.3% at Xenon Pharmaceuticals. Free cash flow was −$201 million at Immunome and −$280 million at Xenon Pharmaceuticals.
Side by side
| Immunome | Xenon Pharmaceuticals | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $7M | $8M |
| Revenue growth | −23.2% | — |
| Revenue growth a year, last 5 years | — | −25.3% |
| Gross margin | — | — |
| Operating margin | −3,228.8% | −4,974.3% |
| Net margin | −3,060.0% | −4,612.1% |
| Free cash flow | −$201M | −$280M |
| Free cash flow margin | −2,890.1% | −3,732.2% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 49.0% | 1.7% |
| Last close | $18.77 | $40.48 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | bought $2.3 million, sold $27.5 million | sold $22.0 million |
| Piotroski F-score | — | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
ImmunomeXenon Pharmaceuticals
Operating margin
Percent of revenue
ImmunomeXenon Pharmaceuticals
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
ImmunomeXenon Pharmaceuticals
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Immunome and Xenon Pharmaceuticals pages.